ES2103274T3 - Metodo de produccion de proteinas de fusion. - Google Patents

Metodo de produccion de proteinas de fusion.

Info

Publication number
ES2103274T3
ES2103274T3 ES90913419T ES90913419T ES2103274T3 ES 2103274 T3 ES2103274 T3 ES 2103274T3 ES 90913419 T ES90913419 T ES 90913419T ES 90913419 T ES90913419 T ES 90913419T ES 2103274 T3 ES2103274 T3 ES 2103274T3
Authority
ES
Spain
Prior art keywords
dna sequence
place
union
restriction
modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90913419T
Other languages
English (en)
Inventor
Stephen D Gillies
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Application granted granted Critical
Publication of ES2103274T3 publication Critical patent/ES2103274T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

LA INVENCION SE REFIERE A METODOS PARA PRODUCIR PROTEINAS DE FUSION COMPRENDIENDO ESTAS ACTIVIDADES BIOLOGICAS DUALES. ESTOS METODOS COMPRENDEN LA PROVISION DE UNA PRIMERA Y DE SEGUNDA SECUENCIA DE ADN QUE CODIFICAN UN PRIMER Y UN SEGUNDO POLIPEPTIDO, RESPECTIVAMENTE, LA DIGESTION DE LA PRIMERA SECUENCIA DE ADN EN UN LUGAR DE RESTRICCION ADYACENTE DE SU TERMINO 3'' O 5'', Y LA LIGADURA DE UNA SECUENCIA ADAPTADORA/ENLAZADORA (1/A) EN EL EXTREMO FINAL DE LA PRIMERA SECUENCIA DE ADN, FORMANDO ASI UN CASET. LA 1/A COMPRENDE, EN UN EXTREMO, ESA PARTE DE LA PRIMERA SECUENCIA DE ADN QUE SE EXTIENDE DESDE UN TERMINO MAS CERCANO DEL LUGAR DE RESTRICCION HASTA EL LUGAR DE RESTRICCION, Y EN EL OTRO EXTREMO, UN LADO DE UN LUGAR DE UNION. UNA CELULA HUESPED EUCARIOTICA SE MODIFICA CON LA CASET Y LA SEGUNDA SECUENCIA DE ADN QUE TIENE, EN UN EXTREMO, UN LADO DE SITIO DE UNION COMPATIBLE CON EL LADO DEL SITIO DE UNION COMPATIBLE CON EL LADO DEL SITIO DE UNION EN LA 1/A. LA CELULA HUESPED MODIFICA ES CULTIVADA PARA EXPRESAR EL ADN MODIFICADO COMO UNA PROTEINA DE FUSION DE CADENA SENCILLA.
ES90913419T 1989-09-20 1990-08-01 Metodo de produccion de proteinas de fusion. Expired - Lifetime ES2103274T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40988989A 1989-09-20 1989-09-20

Publications (1)

Publication Number Publication Date
ES2103274T3 true ES2103274T3 (es) 1997-09-16

Family

ID=23622388

Family Applications (2)

Application Number Title Priority Date Filing Date
ES96113414T Expired - Lifetime ES2187598T3 (es) 1989-09-20 1990-08-01 Metodos para producir proteinas de fusion.
ES90913419T Expired - Lifetime ES2103274T3 (es) 1989-09-20 1990-08-01 Metodo de produccion de proteinas de fusion.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES96113414T Expired - Lifetime ES2187598T3 (es) 1989-09-20 1990-08-01 Metodos para producir proteinas de fusion.

Country Status (9)

Country Link
EP (2) EP0493418B1 (es)
JP (1) JP3051162B2 (es)
AT (2) ATE152174T1 (es)
AU (1) AU633357B2 (es)
CA (1) CA2066612C (es)
DE (2) DE69030579T2 (es)
DK (2) DK0765937T3 (es)
ES (2) ES2187598T3 (es)
WO (1) WO1991004329A1 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6406697B1 (en) 1989-02-23 2002-06-18 Genentech, Inc. Hybrid immunoglobulins
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5498538A (en) * 1990-02-15 1996-03-12 The University Of North Carolina At Chapel Hill Totally synthetic affinity reagents
US5747334A (en) * 1990-02-15 1998-05-05 The University Of North Carolina At Chapel Hill Random peptide library
CA2094495C (en) * 1990-10-22 2007-04-03 David Botstein Methods for modifying and detecting the effects on the interaction of modified polypeptides and target substrates
US5525491A (en) * 1991-02-27 1996-06-11 Creative Biomolecules, Inc. Serine-rich peptide linkers
ES2102007T3 (es) * 1992-01-23 1997-07-16 Merck Patent Gmbh Proteinas de fusion de fragmentos de anticuerpo monomeras y dimeras.
US6103521A (en) * 1995-02-06 2000-08-15 Cell Genesys, Inc. Multispecific chimeric receptors
US5723125A (en) * 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
PT1037927E (pt) 1997-12-08 2004-10-29 Emd Lexigen Res Ct Corp Proteinas de fusao heterodimericas uteis para imunoterapia de abordagem selectiva e estimulacao imunologica geral
DK1196566T3 (da) * 1999-07-12 2006-06-06 Genentech Inc Ekspressionsvektorer og -metoder
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
BR0013231A (pt) 1999-08-09 2002-07-23 Lexigen Pharm Corp Complexos citocina-anticorpo múltiplos
EP1228214A2 (en) 1999-11-12 2002-08-07 MERCK PATENT GmbH Erythropoietin forms with improved properties
JP5179689B2 (ja) 2000-02-11 2013-04-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗体ベース融合タンパク質の循環系内半減期の増強
JP5390055B2 (ja) 2000-06-29 2014-01-15 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 免疫サイトカインの取り込み増強剤との併用治療による抗体−サイトカイン融合タンパク質媒介免疫応答の増強
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
HUP0303428A2 (hu) * 2001-03-07 2004-01-28 Merck Patent Gmbh. Expressziós eljárás hibrid izotípusú antitestcsoportot tartalmazó fehérjékhez
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
KR100900166B1 (ko) 2001-05-03 2009-06-02 메르크 파텐트 게엠베하 재조합 종양 특이적 항체 및 이들의 용도
ATE542137T1 (de) 2001-12-04 2012-02-15 Merck Patent Gmbh Immunocytokine mit modulierter selektivität
CN100432105C (zh) 2002-12-17 2008-11-12 默克专利有限公司 与gd2结合的小鼠14.18抗体的人源化抗体(h14.18)以及其与il-2的融合
PT1699822E (pt) 2003-12-30 2008-07-30 Merck Patent Gmbh Proteínas de fusão de il-7
BRPI0417916A (pt) 2003-12-31 2007-04-10 Merck Patent Gmbh proteìna de fusão de fc-eritropoietina com farmacocinética melhorada
AU2005206277B2 (en) 2004-01-22 2011-06-23 Merck Patent Gmbh Anti-cancer antibodies with reduced complement fixation
RU2437893C2 (ru) 2004-12-09 2011-12-27 Мерк Патент Гмбх Варианты il-7 со сниженной иммуногенностью
EP2295080A3 (en) 2005-07-25 2011-06-22 Emergent Product Development Seattle, LLC B-cell reduction using CD37-specific and CD20-specific binding molecules
EP1966238B1 (en) 2005-12-30 2012-04-25 Merck Patent GmbH Interleukin-12p40 variants with improved stability
EP2270050B1 (en) 2005-12-30 2013-06-05 Merck Patent GmbH Anti-CD19 antibodies with reduced immunogenicity
CN105837690A (zh) 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
PT2132228E (pt) 2008-04-11 2011-10-11 Emergent Product Dev Seattle Imunoterapia de cd37 e sua combinação com um quimioterápico bifuncional
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US9139653B1 (en) 2015-04-30 2015-09-22 Kymab Limited Anti-human OX40L antibodies and methods of treatment
US10071748B2 (en) 2015-09-17 2018-09-11 Sony Corporation System and method for providing driving assistance to safely overtake a vehicle
KR102784293B1 (ko) 2015-09-21 2025-03-20 압테보 리서치 앤드 디벨롭먼트 엘엘씨 Cd3 결합 폴리펩타이드
JP7461741B2 (ja) 2016-06-20 2024-04-04 カイマブ・リミテッド 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
CN110592057B (zh) * 2019-09-27 2022-01-28 昆明理工大学 嵌合裂解酶ILTphg和编码此酶的多核苷酸

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4771002A (en) * 1984-02-24 1988-09-13 Lubrizol Genetics, Inc. Transcription in plants and bacteria

Also Published As

Publication number Publication date
DE69030579D1 (de) 1997-05-28
DK0493418T3 (da) 1997-11-03
EP0493418B1 (en) 1997-04-23
EP0493418A1 (en) 1992-07-08
EP0765937A1 (en) 1997-04-02
AU6335290A (en) 1991-04-18
DE69034022T2 (de) 2003-07-10
CA2066612C (en) 1998-12-08
WO1991004329A1 (en) 1991-04-04
ATE228566T1 (de) 2002-12-15
CA2066612A1 (en) 1991-03-21
AU633357B2 (en) 1993-01-28
JPH05500310A (ja) 1993-01-28
EP0493418A4 (en) 1992-09-02
DK0765937T3 (da) 2003-03-24
DE69034022D1 (de) 2003-01-09
DE69030579T2 (de) 1997-11-13
JP3051162B2 (ja) 2000-06-12
EP0765937B1 (en) 2002-11-27
ES2187598T3 (es) 2003-06-16
ATE152174T1 (de) 1997-05-15

Similar Documents

Publication Publication Date Title
ES2187598T3 (es) Metodos para producir proteinas de fusion.
FI920923A0 (fi) Fusionsproteiner, deras framstaellning samt anvaendning.
ES2072900T3 (es) Expresion elevada de proteinas en levadura.
DK161015C (da) Blanding til anvendelse ved ekstern paavisning og lokalisering af en blodprop
ES2046462T3 (es) Marcadores de activacion de celulas "t".
ATE132902T1 (de) Humane mangan-superoxiddismutase (hmn-sod)
GR880100198A (el) Τμήματα DNA, πολυπεπτίδια και αντισώματα σχετιζόμενα προς τον παράγοντα ιστών του αν?ρώπου.
ES2077666T3 (es) Proteina de union a fibronectina y su preparacion.
AR024318A1 (es) Moleculas de acido nucleico del trigo, celulas de plantas transgenicas y plantas y el uso de las mismas para la produccion de almidon modificado.
ES2163864T3 (es) Secuencias de dna de 2-desoxiglucosa-6-fosfato (2-dog-6-p) como marcador de seleccion en plantas.
AR006250A1 (es) Compuestos y metodos para la inmunoterapia e inmunodiagnostico del cancer prostatico
ATE295416T1 (de) Humanisiertes grünes-fluoreszenzprotein und methoden
CR6538A (es) Anticuerpos de humano, anti-avb3 recombinantes, acidos nucleicos que codifican a los mismos y metodo de uso
BR9808769A (pt) Construção de gene, uso de uma construção de gene, sistema de dois componentes emparelhados, designado para o uso em um hospedeiro mamìfero, e, processo para transferência de um medicamento citotóxico para um sìtio
ATE232237T1 (de) Herstellung von funktionellen, menschlichen urokinaseproteinen
ES8800267A1 (es) Un metodo para obtener un peptido biologicamente activo que tiene afinidad para un ligando proteinaceo o su receptor
ES2073735T3 (es) Nuevos analogos de la cadena b del factor de crecimiento derivado de plaquetas y metodo para su produccion homogenea.
ES2196082T3 (es) Analagos del factor de crecimiento de queratinocitos.
ES2063370T3 (es) Agentes mejorados para el control biologico de insectos y metodos de uso.
ES2144399T3 (es) Clonado del adn de virus de anemia de los pollos.
ES2104596T3 (es) Nuevos polipeptidos, secuencias de adn que permiten su expresion, metodo de preparacion, y utilizacion.
BR9509172A (pt) Proteina de via de complemento nativa sequéncia de dna construção de dna conjugado uso de uma proteína processo para reduzir proteina de via de complemento em um mamifero e formulação farmacéutica
ES2026206T3 (es) Procedimiento para mejorar la expresion de proteina de eucariota.
AR016436A1 (es) Proteina que inhibe a la p27, adn que la codifica, anticuerpos y productos de disociacion de los mismos, acido nucleico antisentido, estructura artificialde acido nucleico y la utilizacion de todo esto en terapia y profilaxis de enfermedades
ES2072868T3 (es) Proteina capaz de unir la fibronectina y su preparacion.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 493418

Country of ref document: ES